Skip to main content
. 2016 Aug;3(8):730–739. doi: 10.1016/S2215-0366(16)30069-4

Table 2.

Treatment efficacy compared with drug placebo

Number of trials (n=54)* Number of patients (n=6652)* Mean YBOCS difference
Full network (n=54) Excluding waiting list controlled trials (n=48)
Drug placebo 23 1515 Reference Reference
Waiting list 6 97 5·62 (0·91 to 10·26) NA
Psychological placebo 6 196 −4·15 (−8·65 to 0·49) −1·90 (−5·62 to 1·91)
SSRIs (class effect) 37 3158 −3·49 (−5·12 to −1·81) −3·62 (−4·89 to −2·34)
Fluoxetine 6 633 −3·46 (−5·27 to −1·58) −3·67 (−5·13 to −2·26)
Fluvoxamine 13 521 −3·60 (−5·29 to −1·95) −3·66 (−4·96 to −2·37)
Paroxetine 8 902 −3·42 (−5·10 to −1·61) −3·51 (−4·81 to −2·14)
Sertraline 7 565 −3·50 (−5·30 to −1·63) −3·68 (−5·14 to −2·30)
Citalopram 2 311 −3·49 (−5·62 to −1·31) −3·60 (−5·25 to −1·91)
Escitalopram 1 226 −3·48 (−5·61 to −1·23) −3·59 (−5·25 to −1·86)
Venlafaxine 2 98 −3·22 (−8·26 to 1·88) −3·21 (−7·01 to 0·69)
Clomipramine 13 831 −4·72 (−6·85 to −2·60) −4·66 (−6·26 to −3·05)
BT 11 287 −14·48 (−18·61 to −10·23) −10·41 (−14·04 to −6·77)
CBT 9 231 −5·37 (−9·10 to −1·63) −7·98 (−11·02 to −4·93)
Cognitive therapy 6 172 −13·36 (−18·40 to −8·21) −9·45 (−13·76 to −5·19)
Hypericum 1 30 −0·15 (−7·46 to 7·12) −0·13 (−5·93 to 5·68)
CBT and fluvoxamine 1 6 −7·50 (−13·89 to −1·17) −8·81 (−13·75 to −3·88)
BT and clomipramine 1 31 −12·97 (−19·18 to −6·74) −11·68 (−16·73 to −6·65)

Data in parentheses are 95% credible intervals. YBOCS=Yale-Brown Obsessive Compulsive Scale. BT=behavioural therapy. CBT=cognitive behavioural therapy. NA=not applicable.

*

Individual trials could be included in more than one treatment category.

Several patients randomly allocated into these psychotherapeutic interventions were allowed to take stable doses of antidepressants and remain on the same dose without further adjustments.